Show simple item record

dc.contributor.authorHou, Han Wei
dc.contributor.authorWu, Lidan
dc.contributor.authorAmador-Munoz, Diana P.
dc.contributor.authorVera, Miguel Pinilla
dc.contributor.authorCoronata, Anna
dc.contributor.authorEnglert, Joshua A.
dc.contributor.authorLevy, Bruce D.
dc.contributor.authorBaron, Rebecca M.
dc.contributor.authorHan, Jongyoon
dc.date.accessioned2017-08-14T14:34:14Z
dc.date.available2017-08-14T14:34:14Z
dc.date.issued2016-01
dc.date.submitted2015-09
dc.identifier.issn1473-0197
dc.identifier.issn1473-0189
dc.identifier.urihttp://hdl.handle.net/1721.1/110938
dc.description.abstractSepsis represents a systemic inflammatory response caused by microbial infection in blood. Herein, we present a novel comprehensive approach to mitigate inflammatory responses through broad spectrum removal of pathogens, leukocytes and cytokines based on biomimetic cell margination. Using a murine model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), we performed extracorporeal blood filtration with the developed microfluidic blood margination (μBM) device. Circulating bacteremia, leukocytes and cytokines in blood decreased post-filtration and significant attenuation of immune cell and cytokine responses were observed 3–5 days after intervention, indicating successful long-term immunomodulation. A dose-dependent effect on long-term immune cell count was also achieved by varying filtration time. As proof of concept for human therapy, the μBM device was scaled up to achieve ∼100-fold higher throughput (∼150 mL h⁻¹). With further multiplexing, the μBM technique could be applied in clinical settings as an adjunctive treatment for sepsis and other inflammatory diseases.en_US
dc.description.sponsorshipUnited States. Defense Advanced Research Projects Agency (N66001-11-1-4182)en_US
dc.language.isoen_US
dc.publisherRoyal Society of Chemistry, Theen_US
dc.relation.isversionofhttp://dx.doi.org/10.1039/c5lc01110hen_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleBroad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapyen_US
dc.typeArticleen_US
dc.identifier.citationHou, Han Wei, et al. “Broad Spectrum Immunomodulation Using Biomimetic Blood Cell Margination for Sepsis Therapy.” Lab on a Chip 16, 4 (2016): 688–699 © 2016 The Royal Society of Chemistryen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Scienceen_US
dc.contributor.departmentMassachusetts Institute of Technology. Research Laboratory of Electronicsen_US
dc.contributor.mitauthorHou, Han Wei
dc.contributor.mitauthorWu, Lidan
dc.contributor.mitauthorHan, Jongyoon
dc.relation.journalLab on a Chipen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsHou, Han Wei; Wu, Lidan; Amador-Munoz, Diana P.; Vera, Miguel Pinilla; Coronata, Anna; Englert, Joshua A.; Levy, Bruce D.; Baron, Rebecca M.; Han, Jongyoonen_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0003-3150-6170
dc.identifier.orcidhttps://orcid.org/0000-0001-7215-1439
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record